JUST IN: President Trump has signed an executive order reclassifying marijuana into a lower-risk category. This is a major shift. The move is designed to reduce regulatory barriers for buying and selling, while simultaneously opening doors for expanded medical research. Cannabis industry stakeholders are celebrating this as a significant win—expect easier market access and more clinical studies on therapeutic applications moving forward. The policy change could have ripple effects across state-level markets and related sectors.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
20 Likes
Reward
20
5
Repost
Share
Comment
0/400
Web3ExplorerLin
· 2025-12-21 11:29
Hypothesis: this cannabis reclassification mirrors the bridge architecture problem in cross-chain protocols—we're essentially creating an interoperability layer between federal restriction networks and state-level market systems. Fascinating oracle moment tbh.
Reply0
BearMarketLightning
· 2025-12-19 15:21
Reclassification of cannabis, this wave can indeed unlock a lot of space for medical research.
View OriginalReply0
MEV_Whisperer
· 2025-12-18 20:06
Wait, is this true? Is marijuana really going to be legalized?
View OriginalReply0
TommyTeacher1
· 2025-12-18 20:04
Wait, has this policy really been approved? Can Trump still be involved in the marijuana legalization?
View OriginalReply0
FrontRunFighter
· 2025-12-18 19:48
yo wait... they're reclassifying weed but nobody's talking about the real play here? watch the market manipulation unfold in real time. this is how the dark forest works—regulatory arbitrage, state-level frontrunning, big players already positioned. textbook extraction disguised as reform lmao
JUST IN: President Trump has signed an executive order reclassifying marijuana into a lower-risk category. This is a major shift. The move is designed to reduce regulatory barriers for buying and selling, while simultaneously opening doors for expanded medical research. Cannabis industry stakeholders are celebrating this as a significant win—expect easier market access and more clinical studies on therapeutic applications moving forward. The policy change could have ripple effects across state-level markets and related sectors.